+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

The impact of highly active antiretroviral combination therapy in HIV infected patients in Glasgow



The impact of highly active antiretroviral combination therapy in HIV infected patients in Glasgow



Health Bulletin 58(4): 309-315



To assess the impact of treatment with highly active antiretroviral therapy on morbidity and mortality in the HIV infected population in Glasgow. Retrospective analysis of the HIV clinical and pharmacy databases in a Department of Infectious Diseases, the major provider of HIV treatment and care in Glasgow. The study population comprised all HIV infected individuals who attended the Department of Infectious Diseases as inpatients or outpatients from April 1994 to March 1999. The main outcome measures were the number of deaths; the number of new AIDS diagnoses; expenditure on drugs for the treatment or prevention of opportunistic infections; hospital admissions of HIV patients; and occupied bed days. The number of patients attending in each year was 215 in 1994-95, rising to 242 in 1998-99. During the same time period there was a 75% reduction in the number of deaths (36 in 1994-95 falling to 10 in 1998-99) and the number of AIDS diagnoses (28 to 7), and a 50% reduction in occupied bed days (3,278 to 1,676) and hospital admissions of HIV infected patients (328 to 164). This occurred at a time when antiviral drug therapy for HIV infection shifted from monotherapy to dual therapy and subsequently to triple or quadruple therapy. In the last two years of the study the majority of treated patients were on a three or four drug regimen. Between 1994 and 1999 there was a marked reduction in the morbidity and mortality of the HIV infected population in Glasgow. This was most likely due to the introduction and widespread use of highly active antiretroviral drug therapy.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 050649189

Download citation: RISBibTeXText

PMID: 12813810


Related references

Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. Journal of Acquired Immune Deficiency Syndromes 30(1): 105-110, 2002

Impact of highly active antiretroviral therapy on the kinetics of CD4+ and CD8+ T cell turnover in HIV-infected patients. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 39: 16, 1999

Impact of highly active antiretroviral therapy on fever of unknown origin in HIV-infected patients. European Journal of Clinical Microbiology & Infectious Diseases 21(2): 137-139, 2002

Impact of highly active antiretroviral therapy on the occurrence of bacteraemia in HIV-infected patients and their epidemiologic characteristics. HIV Medicine 4(2): 127-132, 2003

The impact of highly active antiretroviral therapy (HAART) on visceral leishmaniasis in Spanish patients who are co-infected with HIV. Annals of Tropical Medicine and Parasitology 97(Suppl. 1): 143-147, 2003

Impact of highly active antiretroviral therapy on clinical evolution of genital warts in HIV-infected patients. Aids 13(2): 291-293, 1999

Impact of HIV-1 infection and highly active antiretroviral therapy on the kinetics of CD4+ and CD8+ T cell turnover in HIV-infected patients. Proceedings of the National Academy of Sciences of the United States of America 97(25): 13778-13783, 2000

Impact of highly active antiretroviral therapy in the treatment of HIV-infected patients with systemic non-Hodgkin's lymphoma. Acta Oncologica 41(2): 192-196, 2002

Impact of highly active antiretroviral therapy on the incidence of visceral leishmaniasis in a French HIV-infected cohort patients. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 41: 495, 2001

Impact of highly active antiretroviral therapy on hepatitis C virus protease quasispecies diversity in HIV co-infected patients. Journal of Medical Virology 82(5): 791-798, 2010

Impact of baseline polymorphisms in RT and protease on outcome of highly active antiretroviral therapy in HIV-1-infected African patients. Aids 15(12): 1493-1502, 2001

The impact of highly active antiretroviral therapy on high-risk behaviour of HIV-infected patients in sub-Saharan Africa. Journal of Infection in Developing Countries 7(6): 436-447, 2013

Impact of highly active antiretroviral therapy in the natural history of decompensated liver cirrhosis in HIV-infected patients. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 41: 311, 2001